Cargando…

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

PURPOSE: The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients. MATERIALS AND METHODS: Fifty-seven Korean patientswith advanced GISTwho experienced both imatinib and sun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Son, Myoung Kyun, Ryu, Min-Hee, Park, Joon Oh, Im, Seock-Ah, Kim, Tae-Yong, Lee, Su Jin, Ryoo, Baek-Yeol, Park, Sook Ryun, Kang, Yoon-Koo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398393/ https://www.ncbi.nlm.nih.gov/pubmed/27456941 http://dx.doi.org/10.4143/crt.2016.067

Ejemplares similares

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
por: Park, Sook Ryun, et al.
Publicado: (2016)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
por: Yoo, Changhoon, et al.
Publicado: (2016)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
por: Kang, Y-K, et al.
Publicado: (2013)

Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
por: Kurokawa, Yukinori, et al.
Publicado: (2017)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Debulking of Advanced Gastrointestinal Stromal Tumor With Peritoneal Carcinomatosis Refractory to Imatinib and Sunitinib: A Case Report
por: Rave, Talia E., et al.
Publicado: (2021)

Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study
por: Park, Kwonoh, et al.
Publicado: (2017)

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours
por: Contreras-Hernández, I, et al.
Publicado: (2008)

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo
por: Poole, Chris D., et al.
Publicado: (2014)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
por: Huang, Shaoqing, et al.
Publicado: (2023)

Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection
por: Kang, Gil Ho, et al.
Publicado: (2012)

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
por: Rutkowski, Piotr, et al.
Publicado: (2012)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib: A systematic review
por: Xie, Fuming, et al.
Publicado: (2019)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose
por: Hislop, Jennifer, et al.
Publicado: (2011)

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
por: Kim, Hawk, et al.
Publicado: (2005)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
por: Schvartsman, Gustavo, et al.
Publicado: (2017)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
por: Hsu, Jun-Te, et al.
Publicado: (2017)

Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland
por: Brzozowska, Melania, et al.
Publicado: (2019)

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_n9p5udvc1101n492t184ago22c